Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

COEP

Coeptis Therapeutics Holdings Inc

May 02 • 04:00PM ET

0.3696

Dollar change +0.0298
Percentage change 8.77	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.89	Insider Own	26.31%	Shs Outstand	35.33M	Perf Week	14.78%
Market Cap	13.34M	Forward P/E	-	EPS next Y	-	Insider Trans	0.65%	Shs Float	26.59M	Perf Month	15.72%
Income	-21.27M	PEG	-	EPS next Q	-	Inst Own	13.27%	Short Float	0.66%	Perf Quarter	-35.38%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-1.24%	Short Ratio	0.66	Perf Half Y	-69.33%
Book/sh	0.12	P/B	3.03	EPS next Y	-	ROA	-266.05%	Short Interest	0.17M	Perf Year	-70.67%
Cash/sh	0.04	P/C	9.07	EPS next 5Y	-	ROE	-485.13%	52W Range	0.29 - 2.19	Perf YTD	-52.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-311.69%	ROI	-469.96%	52W High	-83.12%	Beta	-0.94
Dividend TTM	-	Quick Ratio	1.76	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	29.64%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.76	EPS Y/Y TTM	-1013.27%	Oper. Margin	0.00%	RSI (14)	52.85	Volatility	7.90% 10.82%
Employees	7	Debt/Eq	0.28	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.00
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	29.32%	Payout	-	Rel Volume	1.44	Prev Close	0.34
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	262.23K	Price	0.37
SMA20	4.30%	SMA50	-5.35%	SMA200	-55.50%	Trades		Volume	378,608	Change	8.77%

May-02-24 08:47AM	Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting (PR Newswire) +8.77%
Apr-02-24 08:47AM	Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award (PR Newswire) +6.68%
Feb-26-24 09:00AM	Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK (PR Newswire) +9.89%
Feb-07-24 07:30AM	Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections (PR Newswire)
Jan-04-24 07:30AM	Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 (PR Newswire) -10.71%
07:00AM	Loading…
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire) -7.02%
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire) -5.00%
Dec-04-23 07:30AM	Coeptis Therapeutics to Present at the Emerging Growth Conference (PR Newswire)
Oct-31-23 09:01AM	Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 (PR Newswire) -9.74%
07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-24-23 08:30AM	Coeptis Therapeutics Announces $2 Million Private Placement (PR Newswire)
Oct-11-23 07:30AM	Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology (PR Newswire)
Oct-09-23 09:15AM	Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies (PR Newswire)
Oct-04-23 07:30AM	Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (PR Newswire)
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire)
07:30AM	Loading…
Sep-27-23 07:30AM	Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa (PR Newswire) +10.31%
Sep-14-23 07:30AM	Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection (PR Newswire)
Sep-11-23 07:30AM	Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment (PR Newswire) -5.29%
Aug-30-23 01:00PM	Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer (PR Newswire)
Aug-17-23 07:30AM	Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics (PR Newswire)
Aug-01-23 08:00AM	Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic (PR Newswire)
Jun-16-23 04:00PM	Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering (PR Newswire)
Jun-14-23 09:28AM	Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering (PR Newswire) +6.06%
Jun-09-23 07:00AM	Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market (PR Newswire)
May-17-23 08:30AM	Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer (PR Newswire)
May-10-23 03:00PM	Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications (PR Newswire)
Apr-18-23 07:30AM	Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics (PR Newswire) +9.16%
Mar-29-23 09:45AM	Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies (PR Newswire)
Mar-21-23 07:00AM	Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine (PR Newswire)
Feb-07-23 08:00AM	Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling (PR Newswire)
07:30AM	Loading…
Jan-31-23 07:30AM	Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program (PR Newswire) +12.73%
Nov-22-22 07:00AM	Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program (PR Newswire) -6.17%
Nov-15-22 07:00AM	Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell (PR Newswire)
Nov-08-22 07:00AM	Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" Podcast (PR Newswire) -17.13%
Nov-02-22 07:00AM	Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments (PR Newswire) -8.81%
Sep-21-22 07:00AM	Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology (PR Newswire)
May-17-22 07:00AM	Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors (PR Newswire)
Apr-19-22 07:00AM	Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement (PR Newswire)
Apr-13-22 04:05PM	Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod (GlobeNewswire)
07:00AM	Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma (PR Newswire)
Jan-20-22 08:00AM	Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development (PR Newswire)

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DeSilva Tara	Director	Jan 12 '24	Buy	0.58	2,266	1,305	32,266	Jan 16 08:14 PM
Cogley Brian	Chief Financial Officer	Jan 10 '24	Buy	0.67	5,000	3,350	30,000	Jan 17 04:03 PM
Mehalick David	CEO and President	Jan 08 '24	Buy	0.66	20,004	13,263	2,782,615	Jan 09 05:30 PM
Salkind Gene	Director	Jan 05 '24	Buy	0.69	11,600	8,004	284,056	Jan 09 05:31 PM
Yerace Daniel Alexander	VP of Operations	Jan 05 '24	Buy	0.69	10,850	7,486	1,071,455	Jan 09 05:32 PM
Cochran Christopher P.	Director	Jan 05 '24	Buy	0.77	7,000	5,390	37,000	Jan 09 05:30 PM
Mehalick David	CEO and President	Jan 05 '24	Buy	0.69	5,050	3,484	2,762,611	Jan 09 05:30 PM
Salkind Gene	Director	Aug 29 '23	Buy	1.01	4,006	4,046	4,046	Aug 30 03:15 PM
Salkind Gene	Director	Aug 25 '23	Buy	0.91	28,638	26,061	28,638	Aug 30 03:15 PM
Calise Chris	Director	Aug 23 '23	Buy	0.94	11,582	10,879	1,464,897	Aug 31 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COEP

Coeptis Therapeutics Holdings Inc

Upgrade your FINVIZ experience